[Effect of direct current therapy with chemotherapy in 7,12-dimethylbenz[alpha] anthracene (DMBA)-induced rat mammary cancer].
To improve the quality of life of breast cancer patients with local recurrence, we investigated the effect of direct current therapy in combination with chemotherapy. In this study we chose 3mA of direct current and 1mg/kg of CDDP as optimum based upon a prior experimental study. Rats with mammary cancer induced by 7,12-dimethylbenz [alpha] anthracene (DMBA) were divided into four groups based upon therapeutic methods: direct current therapy alone (Group DC), chemotherapy alone (Group CT), direct current therapy with chemotherapy (Group DC+CT) and no treatment (control). The percentage of tumor area 6 weeks after therapy was 30.8% of the metropeutic size in the Group DC+CT, 46.8% in the Group DC, 107% in the Group CT and 267% in the control (Group DC+CT vs the other groups: p < 0.05). The response rate in the Group DC+CT (100%) was significantly higher than that in the other three groups (chi 2-test, p < 0.05). The platinum concentration ratio of both tumor/serum (p < 0.01) and tumor/kidney (p < 0.05) in the Group DC+CT was significantly higher than that in the Group CT. We conclude that direct current therapy in combination with chemotherapy strongly reduces mammary tumor size of rats.
Yokota
T
T
Second Department of Surgery, Gunma University School of Medicine, Maebashi, Japan.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004599:Electric Stimulation Therapy; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology / Q000628:therapy*; D051381:Rats
D015127:9,10-Dimethyl-1,2-benzanthracene; D002945:Cisplatin